Rapidly progressive glomerulonephritis

Summary

Rapidly progressive glomerulonephritis (MONDO:0017236) is a disease and 3 clinical trials. Top therapeutic interventions include methylprednisolone. A subtype of glomerulonephritis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 3

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	rapidly progressive glomerulonephritis
Mondo ID	MONDO:0017236
Orphanet	280569
DOID	DOID:4776
NCIT	C35264
SNOMED CT	236392004
UMLS	C0221239
MedGen	113155
GARD	0025091
MedDRA	10018378
Is cancer (heuristic)	no

Also known as: RPGN

Data availability: 6 cell lines.

Disease family

This is a subtype of glomerulonephritis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › urinary system disorder › kidney disorder › nephritis › glomerulonephritis › rapidly progressive glomerulonephritis

Related subtypes (19): acute poststreptococcal glomerulonephritis, membranoproliferative glomerulonephritis, exudative glomerulonephritis, proliferative glomerulonephritis, focal embolic glomerulonephritis, anti-basement membrane glomerulonephritis, diffuse glomerulonephritis, subacute glomerulonephritis, mesangial proliferative glomerulonephritis, immune-complex glomerulonephritis, IgA glomerulonephritis, membranous glomerulonephritis, lupus nephritis, minimal change disease, granulomatosis with polyangiitis, primary membranoproliferative glomerulonephritis, Pauci-immune glomerulonephritis, immunotactoid glomerulopathy, autoimmune glomerulonephritis

Subtypes (1): chronic rapidly progressive glomerulonephritis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 3.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2/PHASE3	1
PHASE3	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05946564	PHASE3	RECRUITING	A Trial to Evaluate the Efficacy of Pioglitazone to Promote Renal Tolerance in ANCA-associated Vasculitis - RENATO Trial
NCT02647255	PHASE2/PHASE3	TERMINATED	Trial of Plasma Exchange for Severe Crescentic IgA Nephropathy
NCT03201406	Not specified	UNKNOWN	Retrospective Analysis of Renal Prognosis in Patients With Chronic Kidney Disease

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
METHYLPREDNISOLONE	4	1